What Wall Street is saying about Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN)

What Wall Street is saying about Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN)

What Wall Street is saying about Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN)

Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) stock is presently standing at about $4.30 and lots of equity research firms seem to have a target price set on the stock. The median one-year price target of 8 analysts covering the company is $5.50, which suggests the stock could still rise over 22 percent. The highest analyst price target is $13.00, which implies a rally of -102 percent. And a quick view of analyst notes show that 2 are rating the stock a buy while 3 rate ACHN a strong buy. There are 3 equity research firms advocating a Hold and 0 consider it Sell.

Leerink Partners analysts provided their view on Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) recently. The rating firm issued a Outperform rating to this company in a research note released on May 18, 2017. Ladenburg Thalmann analysts disclosed their opinion on Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) recently. The rating firm gave a Buy rating to this stock in a research note published on Feb 02, 2017. According to a research note disclosed on Nov 04, 2016, analysts at Chardan Capital Markets have upped their rating on these shares from Sell to Neutral.

Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) Transactions Roundup

Several insiders were part of recent insider activity for the stock. Its Director FISHERMAN JASON S Purchased 50,000 company shares for 39,600, in a transaction on Dec 22. Following the transaction, the Director is left with a stake of 10,000 shares, currently valued at $43,000. Meanwhile, Chief Financial Officer Fenton Mary Kay purchased 2,500 shares worth $10,275, through a transaction dated Dec 05. Following the completion of the transaction, the insider is left with a stake of 2,500 shares, amounting $10,750. ACHN Chief Commercial Officer Truitt Joseph also purchased 3,500 shares, at a stock price of $4.06. This transaction occurred on Dec 02 totals $14,210. After this transaction, the insider’s stake stands at 3,500 shares, with a market value of $15,050.

Executives hold 0.22 percent of the stock. RA CAPITAL MANAGEMENT, LLC is one of the biggest insider owners in Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN), according to U.S. Securities and Exchange Commission (SEC) filings. The insider owns 13,633,220 shares which have current market value of around $58,622,846.ORBIMED ADVISORS LLC is another major inside shareholder in the company. The insider owns 13,107,200 shares as of 03/31/2017, currently worth $56,360,960. BLACKROCK INC. is ranked as third insider holder of the stock. This insider holds 9,908,372 shares with a market value around $42,606,000 as of recent close.

Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) Earnings Outlook

In Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN)’s latest quarter, EPS moved to $-0.15 from $-0.03 in preceding quarter and revenues reached at $0.00M compared to $15.00M. Analysts had expected Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) to post net income of about $-0.12 per share on $5.62M in revenue. Looking ahead, analysts on average predict that earnings for the current quarter would come in the range of $-0.20 to $-0.16. That is compared with the $-0.14 in EPS it reported during the same period a year ago.

Investing is speculative. When investing your capital is at risk. This site is not intended for use in jurisdictions in which the trading or investments described are prohibited and should only be used by such persons and in such ways as are legally permitted. Your investment may not qualify for investor protection in your country or state of residence, so please conduct your own due diligence. This website is free for you to use but we may receive commission from the companies we feature on this site. Click here for more information.